Revolution Medicines is advancing trials for various cancers, including metastatic PDAC, NSCLC, and CRC, leveraging RAS inhibitors and targeted therapies, alongside benefits from tariffs and analyst upgrades.
3 reports, 1 independent
Updated Jul 16
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Revolution Medicines is advancing trials for various cancers, including metastatic PDAC, NSCLC, and CRC, leveraging RAS inhibitors and targeted therapies, alongside benefits from tariffs and analyst upgrades.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- daraxonrasib received Breakthrough Therapy Designation from the FDA for metastatic pancreatic ductal adenocarcinoma.Sub-event
Company Revolution Medicines benefits from tariffs, analyst upgrades, and advances trials for PDAC, NSCLC, and CRC.1 source
FDA grants Breakthrough Therapy Designation for RVMD's Daraxonrasib in PDAC.1 source
Keep exploring
The entities involved
-
Revolution Medicines (United States)
company in Redwood City, United States
Nothing else this week.
-
Goldman Sachs
American investment bank
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Coverage
Newest first; wire copies grouped- Insider MonkeyRevolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best oversold NASDAQ stocks to buy now. On July 15, Goldman Sa
- Insider MonkeyRevolution Medicines’ Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations Revolution Medicines Inc. (NASDAQ:RVMD) is one of the most promising stoc
- Unknown outlet